Guardant Health and Quest Diagnostics have struck a multi-year deal to make Shield™, the first FDA-approved blood test for colorectal cancer screening, widely available across Quest’s massive network. Starting in early 2026, physicians will be able to order Shield directly through Quest’s EHR system, with patients accessing it at 2,000 service centers and 6,000 in-office phlebotomy sites. By replacing invasive prep with a simple blood draw, the partnership could unlock screening for the 50+ million U.S. adults who currently skip recommended testing — a potential game-changer for early CRC detection and outcomes.
Trending
- Doctronic AI Appoints Dr. Byron Crowe as Chief Medical Officer to Lead Next Stage of Clinical Innovation (Business Wire)
- Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies (Journal of the National Cancer Institute)
- Evidence grows that gut microbes shape mental health, opening doors for new therapies (Medical Xpress)
- Doctors cancel telehealth appointments as Medicare coverage lapses (Roll Call)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- California passes laws targeting PBMs, private equity (Healthcare Dive)
- Event: Future of GI: Modern Solutions for a Modern GI Practice (FoodMarble)
- AI could make it harder to establish blame for medical failings, experts say (The Guardian)